Lyka Labs Ltd
Lyka Labs Ltd (LYKALABS) last reported results for the quarter ended Jun 2026, with sales of ₹42.31 crore and net profit of ₹2.05 crore. The stock last traded at ₹72.6, a market capitalisation of ₹263 crore. Over the past 52 weeks the stock has ranged between ₹44.1 and ₹105. Figures are as of 9 Oct 2026 and are not real time.
Lyka Labs Ltd share price and key metrics
- Current price
- ₹72.6
- Market cap
- ₹263 cr
- Book value
- ₹25.9
- ROE
- -10.2%
- ROCE
- -5.98%
- Dividend yield
- 0.00%
- 52w high / low
- 105/44.1
Metrics as of 9 Oct 2026. Not real time.
Track Lyka Labs Ltd
Cruxal reads every Lyka Labs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Lyka Labs Ltd growth and returns
- 10 Years
- 0%
- 5 Years
- 8%
- 3 Years
- 11%
- TTM
- -3%
- 10 Years
- %
- 5 Years
- 1%
- 3 Years
- -32%
- TTM
- -219%
- 10 Years
- 1%
- 5 Years
- -2%
- 3 Years
- -16%
- 1 Year
- -23%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -2%
- Last Year
- -10%
Lyka Labs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹42.31 cr, up 28.1% from ₹33.03 cr a year earlier. Net profit was ₹2.05 cr, up 107.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 41.16 | 33.8 | 33.43 | 33.03 | 36.66 | 30.73 | 28.03 | 42.31 |
| Expenses | 36.21 | 28.61 | 29.35 | 29.35 | 39.2 | 29.08 | 34.48 | 37.76 |
| Operating profit | 4.95 | 5.19 | 4.08 | 3.68 | -2.54 | 1.65 | -6.45 | 4.55 |
| OPM % | 12.03% | 15.36% | 12.20% | 11.14% | -6.93% | 5.37% | -23.01% | 10.75% |
| Other income | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 | 1.16 | 0.61 | 0.42 |
| Interest | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.7 | 1.01 |
| Depreciation | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 | 2.01 |
| Profit before tax | 2.68 | 3.58 | 3.01 | 1.35 | -4.39 | -0.16 | -8.58 | 1.95 |
| Tax % | 28.36% | 24.30% | 32.89% | 26.67% | -26.65% | -6.25% | -6.06% | -5.13% |
| Net profit | 1.91 | 2.7 | 2.03 | 0.99 | -3.22 | -0.15 | -8.07 | 2.05 |
| EPS (₹) | 0.59 | 0.76 | 0.50 | 0.26 | -0.94 | 0.00 | -2.13 | 0.57 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Lyka Labs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 | 138 |
| Operating profit | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | -3 | -3 |
| OPM % | 21% | -6% | -2.7% | -6% | 23% | 52% | 18% | 14% | 13% | -2.7% | -2.0% |
| Net profit | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | -10 | -9 |
| EPS (₹) | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | -2.81 | -2.50 |
TTM is the trailing twelve months to the most recent quarter.
Lyka Labs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 | 36 |
| Reserves | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 69 | 57 |
| Borrowings | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 | 49 |
| Other liabilities | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 32 | 33 |
| Total liabilities | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 |
| Fixed assets | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 | 87 |
| CWIP | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 | 86 |
| Total assets | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 |
As reported by the company. Total assets equal total liabilities by construction.
Lyka Labs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | 2 | 5 |
| Cash from investing | -13 | -3 | -4 | -0 | -0 | -6 | 7 | -9 | -12 | -9 |
| Cash from financing | -19 | -10 | -23 | 3 | -12 | -63 | -22 | 2 | 5 | 4 |
| Net cash flow | -0 | -3 | -1 | 9 | -3 | 10 | -5 | -6 | -5 | 0 |
| Free cash flow | 18 | 7 | 23 | 4 | 8 | 72 | 15 | -7 | -10 | -6 |
| CFO / operating profit | 143% | -318% | -1,462% | -131% | 49% | 79% | 52% | 21% | 28% | -159% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Lyka Labs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% | 10% | -6% |
| Debtor days | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 | 100 |
| Inventory days | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 | 99 |
| Days payable | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 | 122 |
| Cash conversion cycle | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 | 97 | 76 |
| Working capital days | -357 | -735 | -265 | -242 | -118 | -121 | -0 | 23 | 51 | 23 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Lyka Labs Ltd shareholding pattern
Promoters held 58.45% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.17% and DIIs 0.66%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 58.11% | 58.11% | 58.16% | 58.16% | 58.16% | 58.16% | 58.16% | 58.45% |
| FIIs | 0.15% | 0.15% | 0.24% | 0.16% | 0.17% | 0.17% | 0.29% | 0.17% |
| DIIs | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% |
| Public | 41.08% | 41.07% | 40.93% | 41.02% | 40.99% | 40.99% | 40.89% | 40.73% |
| No. of shareholders | 28,943 | 29,099 | 28,472 | 28,189 | 27,743 | 27,155 | 26,727 | 29,369 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Lyka Labs Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: As per the letter attached
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: As per the letter attached
Read the full analysis - Lyka Labs Ltd announces newspaper publication of financial resultsCompany Updatelow impact
Cruxal's analysis: Lyka Labs Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Lyka Labs Limited concludes 47th AGM with shareholder approval for financial statements and related party transactionsAGM/EGMlow impact
Cruxal's analysis: Lyka Labs Limited has successfully concluded its 47th Annual General Meeting held on 10th…
Read the full analysis - Lyka Labs Limited Reports Strong Q1 FY27 Financial Results with 105.44% Growth in Consolidated Net ProfitCompany Updatehigh impact
Cruxal's analysis: Lyka Labs Limited has released its unaudited financial results for the quarter ended June…
Read the full analysis - Lyka Labs Limited Concludes 47th Annual General Meeting; Approves Material Related Party Transactions with IPCA LaboratoriesAGM/EGMlow impact
Cruxal's analysis: Lyka Labs Limited has successfully concluded its 47th Annual General Meeting held on 10th…
Read the full analysis - Lyka Labs Limited Reports Strong Q1 FY27 Growth with 105% Surge in Consolidated Net ProfitCompany Updatehigh impact
Cruxal's analysis: Lyka Labs Limited has announced robust financial results for Q1 FY27, with consolidated…
Read the full analysis - Lyka Labs Limited Reports Q1 FY2027 Financial Results and Announces Divestment of Subsidiary Lyka BDR International LimitedBoard Meetinghigh impact
Cruxal's analysis: Lyka Labs Limited reported a turnaround in Q1 FY2027 with a standalone net profit of 2.10…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.